Previous 10 | Next 10 |
2023-10-19 19:02:30 ET A new royalty deal was the fuel that powered biotech PTC Therapeutics (NASDAQ: PTCT) stock to a 15% gain on Thursday. That arrangement, which covers PTC's spinal muscular atrophy (SMA) treatment Evrysdi, features a hefty upfront payment that could also bring i...
2023-10-19 08:31:42 ET More on PTC, Roche, etc. Recursion Pharmaceuticals: Wet Lab Meets Silicon, A Tale Of Two Bottom Lines Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche slips after in-line Q3 sales Roche in pact wit...
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion PR Newswire - PTC to receive $1B in upfront cash for approximately 67% of outstanding royalties, with option for additional $500M - - Financing pro...
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , Oct. 16, 2023 /PRNewswire/ -- ...
2023-10-06 10:52:41 ET More on PTC Therapeutics PTC Therapeutics: Struggling Still But Potential Remains PTC Therapeutics, Inc. (PTCT) Q2 2023 Earnings Call Transcript PTC Technologies announces workforce reduction impacting 25% of the company Citi lowers PTC...
2023-09-28 16:57:30 ET More on PTC Therapeutics PTC Therapeutics: Struggling Still But Potential Remains PTC Therapeutics, Inc. (PTCT) Q2 2023 Earnings Call Transcript Citi lowers PTC Therapeutics to neutral amid uncertainty for DMD drug Larimar, Design highe...
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce PR Newswire - Translarna CHMP opinion re-examination request to be submitted - SOUTH PLAINFIELD, N.J. , Sept. 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDA...
NEW YORK, NY / ACCESSWIRE / September 20, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional informati...
2023-09-20 11:55:57 ET More on Health Care Sector: Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecutiv...
2023-09-18 16:38:46 ET More on PTC Therapeutics Seeking Alpha’s Quant Rating on PTC Therapeutics Historical earnings data for PTC Therapeutics Financial information for PTC Therapeutics PTC Therapeutics: Struggling Still But Potential Remains P...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review PR Newswire - PTC to submit a request for re-examination - WARREN, N.J. , June 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announce...
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients PR Newswire - FDA lifts PTC518 partial clinical hold based on PIVOT-HD data - - Conference call and webcast to be held ...